Algorae Pharmaceuticals (ASX:1AI) has announced a major strategic partnership with Cadila Pharmaceuticals, one of India’s largest privately held pharmaceutical companies, marking a significant step in the Australian company’s commercial expansion across key therapeutic markets.
Under a binding term sheet, Algorae will launch two generic medicines in Australia and New Zealand targeting cardiovascular and metabolic disorders. The companies will now move to finalise a definitive License and Supply Agreement, which will formalise the operational framework of the partnership. Once executed, Algorae will begin the process of preparing regulatory submissions to the Therapeutic Goods Administration to enable commercialisation.
Cadila’s reputation for quality and scale has been a key factor in securing the agreement. Headquartered in Ahmedabad, the company operates manufacturing facilities accredited by regulators, including the US FDA, EU, MHRA (UK), WHO and TGA. It distributes products in more than 100 countries and employs over 9,000 people worldwide.
“This partnership represents an important step in executing our commercial strategy and expanding our product portfolio through a world-class manufacturing partner,” said Algorae Chief Commercial Officer Vishal Shah. “Our focus now is on finalising the definitive agreement and preparing for regulatory submissions.”
The announcement reflects Algorae’s growing ambitions to leverage its AI-enabled pharmaceutical development platform to build a broader product portfolio. While the company has focused on advanced drug discovery using its proprietary AlgoraeOS system, this deal gives it an immediate foothold in commercially established therapeutic areas.
Cadila, founded in 1951, has built a strong global reputation through a mix of scientific innovation and large-scale manufacturing capabilities. The partnership gives Algorae access to its extensive pipeline and manufacturing expertise, supporting rapid market entry in Australia and New Zealand.
As regulatory processes progress, Algorae will update shareholders on timelines for approval and expected revenue contributions. The agreement positions the company to diversify its revenue base while building longer-term innovation programs around AI-driven drug discovery.
For both companies, the partnership signals a shared commitment to expanding affordable access to high-quality medicines in markets where demand for cardiovascular and metabolic therapies continues to grow.